Drug Companies Disenchanted; Device Companies Depart
The question is, are both Bristol-Myers Squibb and Pfizer preparing to sell their orthopedics businesses and get out of medical devices altogether? And where would buyers for both be found?
You may also be interested in...
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to include two new products, including Sanofi's Sarclisa for treating adults with relapsed and refractory multiple myeloma The list, which contains information dating back to January 2018, includes brand name, generic name, company, therapeutic indication, date of marketing authorization and product type (eg, medicine, vaccine, biologic).
Progress for two US-based companies in the race to develop a COVID-19 vaccine.
After double-digit growth in formulation sales across geographies in the fourth quarter, Aurobindo expects to continue the momentum this fiscal year. Meanwhile, it might look for partners for its biologics business, which is now transferred to its fully owned subsidiary for $48m.